Novavax COVID Vaccine FDA Brief - So Now FDA Has Concerns

Novavax COVID Vaccine FDA Brief - So Now FDA Has Concerns

FDA has published the briefing document to be reviewed by their vaccine approval committee tomorrow (on June 7th, 2022). Let's review the overall efficacy, allergic reactions, myocarditis, neurological issues, and deaths.

If you like this content and want more, I am doing a special lifetime membership offer. Click here:
https://www.drbeen.com/yt-special/

Want to support this work?:
Buy me a coffee :-) https://www.buymeacoffee.com/DrMobeenSyed
Become my patron: https://www.patreon.com/mobeensyed?fan_landing=true
PayPal: https://paypal.me/mobeensyed?locale.x=en_US

My substack: https://mobeensyedmd.substack.com/

#drbeen #koolbeens #COVID

Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

URL list from Monday, Jun. 6 2022
Novavax Investor Relations - Press releases & statements
https://ir.novavax.com/Novavax-Statement-on-US-FDA-Briefing-Document-Related-to-Myocarditis-Pericarditis

Novavax Investor Relations - Press releases & statements
https://ir.novavax.com/Novavax-Files-in-the-United-Kingdom-for-Expanded-Conditional-Marketing-Authorization-of-COVID-19-Vaccination-as-a-Booster-in-Adults-Aged-18-and-Over

Novavax Investor Relations - Press releases & statements
https://ir.novavax.com/press-releases?l=100